查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症生物标记市场：趋势、预测和竞争分析（~2030 年）
市场调查报告书
商品编码
1386082

全球癌症生物标记市场：趋势、预测和竞争分析（~2030 年）

Cancer Biomarkers Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

癌症生物标记趋势和预测

预计2024年至2030年，全球癌症生物标记市场规模将以14.5%的年复合成长率成长，到2030年将达到约377亿美元。这个市场的主要驱动因素是癌症治疗中个人化医疗的日益导向、人们对癌症早期检测重要性的认识不断提高以及政府对癌症研究的支持不断增加。全球癌症生物标记市场的未来充满希望，诊断、研发、预测和风险管理市场充满机会。

癌症生物标誌物市场洞察

Lucintel 预测，由于乳癌发生率上升以及对该疾病诊断认识的提高，乳癌在预测期内仍将是最大的部分。

在这个市场中，由于癌症盛行率不断增加以及癌症筛检计画的可用性不断增加，诊断仍然是最大的细分市场。

由于拥有完善的医疗保健系统、不断上升的癌症发病率以及容易获得先进医疗技术，北美在预测期内可能仍然是最大的地区。

市场规模/估计：市场规模/估计：以金额预测的癌症生物标记市场规模（10 亿美元）

趋势和预测分析：各细分市场和地区的市场趋势（2018-2023）和预测（2024-2030）

細項分析：按类型、癌症类型、分析技术、应用和区域等各个细分市场估计癌症生物标记市场规模（十亿美元）

区域分析：北美、欧洲、亚太地区和世界其他地区的癌症生物标记市场细分

成长机会：按类型、癌症类型、分析技术、应用和地区对癌症生物标记市场的成长机会进行分析。

策略分析：癌症生物标记市场的併购、新产品开发、竞争形势等。

基于波特五力模型的产业竞争实力分析

常问问题

Q.1 癌症生物标记的市场规模有多大？

答：到 2030 年，全球癌症生物标记市场预计将达到 377 亿美元。

Q.2 癌症生物标记市场的成长预测如何？

答案从2024年到2030年，全球癌症生物标记市场预计将以14.5%的年复合成长率成长。

Q.3 影响癌症生物标记市场成长的关键驱动因素有哪些？

答：这个市场的主要驱动力是癌症治疗中个人化医疗的日益导向、人们对癌症早期检测重要性的认识不断提高以及政府对癌症研究的支持不断增加。

Q4.癌症生物标记市场的主要细分市场有哪些？

答： 癌症生物标记市场的未来充满希望，诊断、研发、预测和风险管理市场充满商机。

Q5. 癌症生物标记市场的主要企业有哪些？

答主要的癌症生物标记公司有：

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen NV
  • Bio-Rad Laboratories

Q6. 未来癌症生物标记市场中哪个细分市场会是最大的？

答： Lucintel 预计，由于乳癌发生率不断上升以及诊断该疾病的意识不断增强，乳癌在预测期内仍将是其最大的细分市场。

Q7.未来年度哪个地区将成为最大的癌症生物标记市场？

由于拥有完善的医疗保健系统、不断上升的癌症发病率以及易于获得先进医疗技术，北美在预测期内仍将是最大的地区。

Q.8 是否可以客製化报告？

答：是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球癌症生物标记市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势与预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球癌症生物标记市场趋势（2018-2023）与预测（2024-2030）
  • 全球癌症生物标记市场：按类型
    • 蛋白质
    • 遗传上
    • 其他的
  • 全球癌症生物标记市场：按癌症类型
    • 肺
    • 胸部
    • 白血病
    • 黑色素瘤
    • 大肠直肠
    • 摄护腺
    • 甲状腺
    • 肾
    • 其他的
  • 全球癌症生物标记市场：依分析技术分类
    • 体学
    • 影像
    • 免疫检测
    • 生物资讯学
    • 其他的
  • 全球癌症生物标记市场：按应用分类
    • 诊断
    • 研究与开发
    • 预后
    • 危机管理
    • 其他的

第4章市场趋势与预测分析：按地区（2018-2030）

  • 全球癌症生物标记市场：按地区
  • 北美癌症生物标记市场
  • 欧洲癌症生物标记市场
  • 亚太地区癌症生物标记市场
  • 其他地区的癌症生物标记市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球癌症生物标记市场成长机会
    • 按癌症类型分類的全球癌症生物标记市场成长机会
    • 全球癌症生物标记市场成长机会（按分析技术）
    • 全球癌症生物标记市场成长机会（按应用）
    • 全球癌症生物标记物市场成长机会（按地区）
  • 全球癌症生物标记市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球癌症生物标记市场的能力
    • 全球癌症生物标记市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN NV
  • Bio-Rad Laboratories
简介目录

Cancer Biomarkers Trends and Forecast

The future of the global cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

A more than 150-page report is developed to help in your business decisions.

Cancer Biomarkers by Segment

The study includes a forecast for the global cancer biomarkers by type, cancer, profiling technology, application, and region.

Cancer Biomarkers Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Protein
  • Genetic
  • Others

Cancer Biomarkers Market by Cancer [Shipment Analysis by Value from 2018 to 2030]:

  • Lung
  • Breast
  • Leukemia
  • Melanoma
  • Colorectal
  • Prostate
  • Thyroid
  • Kidney
  • Others

Cancer Biomarkers Market by Profiling Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Omics
  • Imaging
  • Immunoassay
  • Bioinformatics
  • Others

Cancer Biomarkers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnostics
  • R&D
  • Prognostics
  • Risk Management
  • Others

Cancer Biomarkers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Biomarkers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer biomarkers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Cancer Biomarkers Market Insights

Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Within this market, diagnostic will remain the largest segment due to increasing prevalence of cancer and growing availability of cancer screening programs.

North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Features of the Global Cancer Biomarkers Market

Market Size Estimates: Cancer biomarkers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer biomarkers market size by various segments, such as by type, cancer type, profiling technology, application, and region in terms of ($B).

Regional Analysis: Cancer biomarkers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, cancer types, profiling technologies, applications, and regions for the cancer biomarkers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer biomarkers market size?

Answer: The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030.

Q.2 What is the growth forecast for cancer biomarkers market?

Answer: The global cancer biomarkers market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer biomarkers market?

Answer: The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

Q4. What are the major segments for cancer biomarkers market?

Answer: The future of the cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.

Q5. Who are the key cancer biomarkers market companies?

Answer: Some of the key cancer biomarkers companies are as follows:

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Q6. Which cancer biomarkers market segment will be the largest in future?

Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Q7. In cancer biomarkers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer biomarkers market by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), application (diagnostics, R&D, prognostics, risk management, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Biomarkers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Biomarkers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Biomarkers Market by Type
    • 3.3.1: Protein
    • 3.3.2: Genetic
    • 3.3.3: Others
  • 3.4: Global Cancer Biomarkers Market by Cancer Type
    • 3.4.1: Lung
    • 3.4.2: Breast
    • 3.4.3: Leukemia
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal
    • 3.4.6: Prostate
    • 3.4.7: Thyroid
    • 3.4.8: Kidney
    • 3.4.9: Others
  • 3.5: Global Cancer Biomarkers Market by Profiling Technology
    • 3.5.1: Omics
    • 3.5.2: Imaging
    • 3.5.3: Immunoassay
    • 3.5.4: Bioinformatics
    • 3.5.5: Others
  • 3.6: Global Cancer Biomarkers Market by Application
    • 3.6.1: Diagnostics
    • 3.6.2: R&D
    • 3.6.3: Prognostics
    • 3.6.4: Risk Management
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Biomarkers Market by Region
  • 4.2: North American Cancer Biomarkers Market
    • 4.2.2: North American Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.3: European Cancer Biomarkers Market
    • 4.3.1: European Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.3.2: European Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.4: APAC Cancer Biomarkers Market
    • 4.4.1: APAC Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.4.2: APAC Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.5: ROW Cancer Biomarkers Market
    • 4.5.1: ROW Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.5.2: ROW Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Biomarkers Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Biomarkers Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Cancer Biomarkers Market by Profiling Technology
    • 6.1.4: Growth Opportunities for the Global Cancer Biomarkers Market by Application
    • 6.1.5: Growth Opportunities for the Global Cancer Biomarkers Market by Region
  • 6.2: Emerging Trends in the Global Cancer Biomarkers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Biomarkers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Biomarkers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Thermo Fisher Scientific
  • 7.3: Illumina
  • 7.4: QIAGEN N.V.
  • 7.5: Bio-Rad Laboratories